Property Name |
Property Value |
Unit |
Raw Value |
Raw Unit |
Annotation |
Factor |
Reference |
AUC |
2103.0 |
ng.h/ml |
2103.0 |
ng.h/ml |
PO, oral; |
|
DRUGBANK |
AUC |
4544.0 |
ng.h/ml |
4544.0 |
ng.h/ml |
PO, oral; food; |
food ↑ ; |
DRUGBANK |
Bioavailability |
95.4 |
% |
95.4 |
% |
PO, oral; food; |
food ↑ ; |
DRUGBANK |
C Max |
209.0 |
ng/ml |
209.0 |
ng/ml |
PO, oral; |
|
DRUGBANK |
C Max |
301.0 |
ng/ml |
301.0 |
ng/ml |
PO, oral; food; |
food ↑ ; |
DRUGBANK |
C Max |
185.0 |
ng/ml |
185±51 |
ng/ml |
PO, oral; |
|
The Pharmacological Basis of Therapeutics |
C Max |
231.0 |
ng/ml |
231±49 |
ng/ml |
PO, oral; Active metabolite; |
|
The Pharmacological Basis of Therapeutics |
C Max |
571.0 |
ng/ml |
571±74 |
ng/ml |
PO, oral; Active metabolite; |
|
The Pharmacological Basis of Therapeutics |
C Max |
202.0 |
ng/ml |
202±54 |
ng/ml |
PO, oral; Active metabolite; |
|
The Pharmacological Basis of Therapeutics |
T Max |
2.6 |
h |
2.6 |
h |
|
|
DRUGBANK |
T Max |
4.3 |
h |
4.3 |
h |
Active metabolite; |
|
DRUGBANK |
T Max |
2.3 |
h |
2.28 |
h |
PO, oral; |
|
DRUGBANK |
T Max |
3.1 |
h |
3.05 |
h |
PO, oral; food; |
food ↑ ; |
DRUGBANK |
T Max |
1.0 |
h |
1.0 |
h |
PO, oral; |
|
The Pharmacological Basis of Therapeutics |
T Max |
2.9 |
h |
2.9±0.6 |
h |
PO, oral; Active metabolite; |
|
The Pharmacological Basis of Therapeutics |
T Max |
1.8 |
h |
1.8±0.5 |
h |
PO, oral; Active metabolite; |
|
The Pharmacological Basis of Therapeutics |
T Max |
3.1 |
h |
3.1±0.9 |
h |
PO, oral; Active metabolite; |
|
The Pharmacological Basis of Therapeutics |
Clearance |
5.6 |
L/h/kg |
93.0 |
ml/min/kg |
apparent clearance; |
|
The Pharmacological Basis of Therapeutics |
Volume of Distribution |
10.0 |
L/kg |
10.0 |
L/kg |
Apparent volume of distribution; |
|
The Pharmacological Basis of Therapeutics |
Half-life |
1.4 |
h |
1.4 |
h |
|
|
DRUGBANK |
Half-life |
1.3 |
h |
1.3±0.3 |
h |
Oral single dose; |
chronic liver disease ↑ ; |
The Pharmacological Basis of Therapeutics |
Half-life |
11.2 |
h |
11.2±2.3 |
h |
Active metabolite; Oral single dose; |
chronic liver disease ↑ ; |
The Pharmacological Basis of Therapeutics |
Half-life |
2.8 |
h |
2.8±0.4 |
h |
Active metabolite; Oral single dose; |
chronic liver disease ↑ ; |
The Pharmacological Basis of Therapeutics |
Half-life |
10.1 |
h |
10.1±2.3 |
h |
Active metabolite; Oral single dose; |
chronic liver disease ↑ ; |
The Pharmacological Basis of Therapeutics |
Toxicity LD50 |
1000.0 |
mg/kg |
>1 |
g/kg |
PO, oral; mouse; Rattus, Rat; rabbit; |
|
DRUGBANK |
Toxicity LD50 |
1000.0 |
mg/kg |
>1000 |
mg/kg |
PO, oral; mouse; Rattus, Rat; rabbit; |
|
T3DB |
Eliminate Route |
49.0 |
% |
42-56 |
% |
Urinary excretion; |
|
DRUGBANK |
Eliminate Route |
14.4 |
% |
14.2-14.6 |
% |
Faeces excretion; |
|
DRUGBANK |
Eliminate Route |
1.0 |
% |
<1 |
% |
Urinary excretion; PO, oral; Unchanged drug; |
|
The Pharmacological Basis of Therapeutics |
Protein Binding |
98.0 |
% |
98 |
% |
|
|
DRUGBANK |
Protein Binding |
90.0 |
% |
>90 |
% |
|
|
The Pharmacological Basis of Therapeutics |